Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.

ABSTRACT: Identifying genetic contributors to cognitive impairments in psychosis-spectrum disorders can advance understanding of disease pathophysiology. Although CNS medications are known to affect cognitive performance, they are often not accounted for in genetic association studies. In this study, we performed a genome-wide association study (GWAS) of global cognitive performance, measured as composite z-scores from the Brief Assessment of Cognition in Schizophrenia (BACS), in persons with psychotic disorders and controls (N = 817; 682 cases and 135 controls) from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Analyses accounting for anticholinergic exposures from both psychiatric and non-psychiatric medications revealed five significantly associated variants located

SUBMITTER: Eum S 

PROVIDER: S-EPMC8358015 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature